Short-term trial of etanercept in Behcet's disease: A double blind, placebo controlled study

Abstract

Objective. To determine the effect of the tumor necrosis factor-a blocker-etanercept on the pathergy and monosodium urate (MSU) status and on the mucocutaneous and articular manifestations of patients with Behcet's disease (BD).